

San Francisco: September 2016

“Accelero Biostructures, Inc., has received non-dilutive funding from the National Institutes of Health (NIH) under the Small Business Innovation Research (SBIR) program. Accelero Biostructures develops technologies and tools for accelerating structure-based drug discovery and protein engineering using its deep expertise in high-throughput protein x-ray crystallography.

“We are very excited to receive this highly competitive funding from NIH, which validates our R&D and business plans enabling us to progress on our mission to drive early drug discovery to eventually develop new products to help people around the world”, said Debanu Das, Co-Founder and CEO.

The funds will be used to develop parts of Accelero Bio’s platform to provide novel leads for developing new therapeutics. X-ray crystallography is the gold standard for determining the exact binding orientation of molecules, which is an essential step in this process. Leveraging the core team that was previously part of the high-throughput protein structure group of the NIH Protein Structure Initiative program at the Joint Center for Structural Genomics (JCSG) at Stanford Synchrotron Radiation Lightsource (SSRL), SLAC National Accelerator Laboratory (SLAC), Menlo Park, California, is key in the process, bringing on board approximately 40 years of combined team experience in the field. The developments will also benefit in several other applications in the field of protein x-ray crystallography.

Accelero Biostructures was formed in January 2015 with support from the University of California’s QB3 program and has been working with customers and partners for over a year. “We aim to dramatically increase the efficiency and reduce the cost of developing novel lead molecules for preclinical testing. Platform development will also help in providing additional tools and technologies to the company’s customers and partners.”, said Ashley Deacon, Co-Founder and CSO.